[go: up one dir, main page]

NO20032156D0 - Treatment of anxiety disorders - Google Patents

Treatment of anxiety disorders

Info

Publication number
NO20032156D0
NO20032156D0 NO20032156A NO20032156A NO20032156D0 NO 20032156 D0 NO20032156 D0 NO 20032156D0 NO 20032156 A NO20032156 A NO 20032156A NO 20032156 A NO20032156 A NO 20032156A NO 20032156 D0 NO20032156 D0 NO 20032156D0
Authority
NO
Norway
Prior art keywords
treatment
anxiety disorders
anxiety
disorders
Prior art date
Application number
NO20032156A
Other languages
Norwegian (no)
Other versions
NO20032156L (en
Inventor
Holly Read Thomasson
David Michelson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20032156D0 publication Critical patent/NO20032156D0/en
Publication of NO20032156L publication Critical patent/NO20032156L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20032156A 2000-11-15 2003-05-13 Treatment of anxiety disorders NO20032156L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US26536201P 2001-01-31 2001-01-31
PCT/US2001/027801 WO2002040006A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Publications (2)

Publication Number Publication Date
NO20032156D0 true NO20032156D0 (en) 2003-05-13
NO20032156L NO20032156L (en) 2003-05-13

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032156A NO20032156L (en) 2000-11-15 2003-05-13 Treatment of anxiety disorders

Country Status (16)

Country Link
EP (1) EP1395253A2 (en)
JP (1) JP2004529073A (en)
KR (1) KR20030051812A (en)
CN (1) CN1822825A (en)
AU (1) AU2002217757A1 (en)
BR (1) BR0115301A (en)
CA (1) CA2426069A1 (en)
CZ (1) CZ20031339A3 (en)
EA (1) EA200300567A1 (en)
HR (1) HRP20030384A2 (en)
IL (1) IL155874A0 (en)
MX (1) MXPA03004190A (en)
NO (1) NO20032156L (en)
PL (1) PL366119A1 (en)
SK (1) SK5422003A3 (en)
WO (1) WO2002040006A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005768B1 (en) * 2001-03-06 2005-06-30 Эли Лилли Энд Компани Inhibitor of monoamine uptake
CN1674907A (en) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 Use of reboxetine for the treatment of hot flashes
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
KR20060121178A (en) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 Selective norepinephrine reuptake inhibitors for the treatment of personality changes due to hot flashes, impulse control disorders and general medical conditions
WO2009089479A2 (en) * 2008-01-09 2009-07-16 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20120220665A1 (en) * 2009-11-03 2012-08-30 Mayo Foundation For Medical Education And Research Inhibiting Neurotransmitter Reuptake
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
JP2022519541A (en) * 2019-02-01 2022-03-24 ホフマン・テクノロジーズ・エルエルシー Compositions and Methods for Treating Anxiety-Related Disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041878A1 (en) * 1996-05-07 1997-11-13 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (en) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Use of reboxetine for treating obsessive compulsive disorder and panic disorder
ES2247572T3 (en) * 1999-07-01 2006-03-01 PHARMACIA & UPJOHN COMPANY LLC (S, S) -REBOXETINE TO TREAT MIGRAINE HEADS.

Also Published As

Publication number Publication date
AU2002217757A1 (en) 2002-05-27
WO2002040006A3 (en) 2003-12-24
BR0115301A (en) 2004-12-14
MXPA03004190A (en) 2003-09-22
CZ20031339A3 (en) 2003-10-15
CA2426069A1 (en) 2002-05-23
PL366119A1 (en) 2005-01-24
SK5422003A3 (en) 2003-12-02
NO20032156L (en) 2003-05-13
JP2004529073A (en) 2004-09-24
WO2002040006A2 (en) 2002-05-23
IL155874A0 (en) 2003-12-23
HRP20030384A2 (en) 2003-08-31
CN1822825A (en) 2006-08-23
EP1395253A2 (en) 2004-03-10
EA200300567A1 (en) 2004-10-28
KR20030051812A (en) 2003-06-25

Similar Documents

Publication Publication Date Title
NO20040097L (en) Combinations for the treatment of inflammatory disorders
NO20024273L (en) Therapeutic uses of PPAR mediators
NO20031442D0 (en) Morpholine-acetamide derivatives for the treatment of inflammatory diseases
GB0007193D0 (en) Treatment of movrmrnt disorders
NO20026263L (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
NO20041386L (en) Combinations for the treatment of immuno-inflammatory disorders
NO20024775D0 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
NO20024486L (en) Improved treatment of neovascularization
NO20020062D0 (en) Treatment of neurotic disorders
DE60236743D1 (en) FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES
NO20023425L (en) Procedures for relieving anxiety
NO20032156L (en) Treatment of anxiety disorders
ID27214A (en) TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS
NO20026219L (en) Compounds for the treatment of impaired fundic relaxation
NO20024776L (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
NO20024777L (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
NO20024236D0 (en) Treatment of psoriasis
NO20023803L (en) Use of mirtazapine for the treatment of sleep disorders
NO20010390D0 (en) Treatment of anxiety disorders
DK1309322T3 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
NO20030717D0 (en) Compounds for the treatment of addiction disorders
NO20024331D0 (en) Treatment of disorders related to the serotonergic system
NO20030767D0 (en) Treatment of burns
NO20002538D0 (en) Detection of respiratory disorders
HK1063438A (en) Treatment of anxiety disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application